CHEPLAPHARM Arzneimittel GmbH continues its successful expansion strategy by purchasing three further global niche products.
The transaction involves three global niche products that are in high demand for oncology and infectious therapy, respectively: FUNGIZONE® (amphotericin B) is used to treat seriously ill and immunocompromised patients with progressive, potentially life-threatening, fungal infections. VEPESID® (etoposide) and ETOPOPHOS® (etoposide phosphate) are mainly used to treat tumors and fight leukemia.
By acquiring the global rights to this product package, CHEPLAPHARM has succeeded in expanding its presence in strategically important markets. This refers in particular to the French market.
“With this substantial deal, the partnership and trusting cooperation with Bristol-Myers Squibb have been further strengthened - we are very pleased about that. The product package contributes significantly to the future diversification of our global portfolio and thus once again confirms our successful Buy And Build Strategy", says CEO Sebastian F. Braun.
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com